Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
Nucleome Therapeutics ('Nucleome' or 'the Company'), a company tackling the molecular causes of inflammatory diseases through a ...
Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc.
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...
Trading under DCOY to commence on January 8, 2026Company’s proprietary peptide-conjugate platform leverages AI-enabled computational ...
Clinical Trials in Cancer Cachexia, Inflammatory Bowel Disease and Retinal Disorders are Planned MONTVALE, N. J., Jan. 07, 2026 (GLOBE ...
(Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it plans to file a Marketing ...
-- Proceeds to drive global Phase 3 trial for ASP-1929, targeting BLA submission to the U.S. FDA in 2028 -- Financing led by international life science fund TaiAx, with participation from the largest ...
Expansion of lead KIF18Ai program in lung, head and neck cancers following early positive resultsGenetic biomarker signatures show early correlation with KIF18Ai clinical responseCompany reports ...
After shepherding the company through its first approval and the successful launch of blockbuster autoimmune drug Vyvgart, ...
News-Medical.Net on MSN
Study reveals bioactive compounds driving Borage's diverse therapeutic benefits
For centuries, Borago officinalis - commonly known as Borage or the Starflower - has been a staple of traditional medicine.
The FDA clearance enables Abpro and its co-development partner Celltrion Inc to begin a Phase 1 clinical trial evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback